EA202192008A1 - Lilrb3-связывающие молекулы и варианты их применения - Google Patents

Lilrb3-связывающие молекулы и варианты их применения

Info

Publication number
EA202192008A1
EA202192008A1 EA202192008A EA202192008A EA202192008A1 EA 202192008 A1 EA202192008 A1 EA 202192008A1 EA 202192008 A EA202192008 A EA 202192008A EA 202192008 A EA202192008 A EA 202192008A EA 202192008 A1 EA202192008 A1 EA 202192008A1
Authority
EA
Eurasian Patent Office
Prior art keywords
lilrb3
variants
application
binding molecules
antibodies
Prior art date
Application number
EA202192008A
Other languages
English (en)
Russian (ru)
Inventor
Ричард Брокс
Жаклин М. Мэйсон
Марк Р. Брэй
Original Assignee
Юниверсити Хелт Нетворк
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Юниверсити Хелт Нетворк filed Critical Юниверсити Хелт Нетворк
Publication of EA202192008A1 publication Critical patent/EA202192008A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EA202192008A 2019-01-18 2020-01-16 Lilrb3-связывающие молекулы и варианты их применения EA202192008A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962794064P 2019-01-18 2019-01-18
PCT/CA2020/050042 WO2020146946A1 (en) 2019-01-18 2020-01-16 Lilrb3-binding molecules and uses therefor

Publications (1)

Publication Number Publication Date
EA202192008A1 true EA202192008A1 (ru) 2021-10-21

Family

ID=71612981

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202192008A EA202192008A1 (ru) 2019-01-18 2020-01-16 Lilrb3-связывающие молекулы и варианты их применения

Country Status (14)

Country Link
US (1) US12404327B2 (enExample)
EP (1) EP3911680A4 (enExample)
JP (1) JP7631203B2 (enExample)
KR (1) KR20210118116A (enExample)
CN (1) CN113454123A (enExample)
AU (1) AU2020209367A1 (enExample)
BR (1) BR112021014102A2 (enExample)
CA (1) CA3126295A1 (enExample)
EA (1) EA202192008A1 (enExample)
IL (1) IL284781A (enExample)
MX (1) MX2021008507A (enExample)
SG (1) SG11202107663UA (enExample)
TW (1) TWI852980B (enExample)
WO (1) WO2020146946A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI832183B (zh) * 2019-08-06 2024-02-11 香港商新旭生技股份有限公司 結合至病理性tau種類之抗體及其用途
CN116963747A (zh) * 2020-12-03 2023-10-27 德克萨斯大学体系董事会 用于鉴定lilrb阻断抗体的方法
EP4255451A4 (en) * 2020-12-03 2025-01-01 The Board Of Regents Of The University Of Texas System Methods for identifying lilrb-blocking antibodies
CN115925941B (zh) * 2022-06-08 2026-04-03 北京科诺信诚科技有限公司 靶向人lilrb4的纳米抗体及其应用
WO2025231127A1 (en) * 2024-05-02 2025-11-06 The Regents Of The University Of California Compositions and methods for intracellular antigen targeting with antibodies

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JP2007512846A (ja) 2003-12-04 2007-05-24 ゼンコー・インコーポレイテッド 増加した宿主ストリング含有量を有する変異体タンパク質の生成方法およびその組成物
JP5947727B2 (ja) 2010-01-20 2016-07-06 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗ｉｌｔ５抗体およびｉｌｔ５結合抗体断片による免疫調節
AU2011207253B2 (en) * 2010-01-20 2015-02-12 Merck Sharp & Dohme Corp. Anti-ILT5 antibodies and ILT5-binding antibody fragments
AU2013234046B2 (en) 2012-03-16 2017-09-07 University Health Network Methods and compositions for modulating Toso activity
US20150174203A1 (en) 2012-05-30 2015-06-25 Icahn School Of Medicine At Mount Sinai Compositions And Methods For Modulating Pro-Inflammatory Immune Response
CA2917077A1 (en) 2013-07-03 2015-01-08 University Health Network Antibodies to toso
CA2961439A1 (en) 2014-11-05 2016-05-12 Genentech, Inc. Anti-fgfr2/3 antibodies and methods using same
EP3256163A4 (en) * 2015-02-11 2018-10-10 University Health Network Methods and compositions for modulating lilr proteins
CN107660150B (zh) * 2015-03-05 2023-10-24 Ab2生物股份有限公司 Il-18结合蛋白(il-18bp)和抗体在炎性疾病中
CA3218106A1 (en) * 2015-03-06 2016-09-15 The Board Of Regents Of The University Of Texas System Anti-lilrb antibodies and their use in detecting and treating cancer
US11787858B2 (en) * 2016-12-22 2023-10-17 Icahn School Of Medicine At Mount Sinai Anti-LILRB3 antibodies and methods of use thereof

Also Published As

Publication number Publication date
BR112021014102A2 (pt) 2021-09-21
US20220089723A1 (en) 2022-03-24
MX2021008507A (es) 2021-09-21
TW202031685A (zh) 2020-09-01
KR20210118116A (ko) 2021-09-29
WO2020146946A1 (en) 2020-07-23
US12404327B2 (en) 2025-09-02
JP2022517809A (ja) 2022-03-10
SG11202107663UA (en) 2021-08-30
CA3126295A1 (en) 2020-07-23
AU2020209367A1 (en) 2021-08-19
TWI852980B (zh) 2024-08-21
JP7631203B2 (ja) 2025-02-18
IL284781A (en) 2021-08-31
CN113454123A (zh) 2021-09-28
EP3911680A1 (en) 2021-11-24
EP3911680A4 (en) 2022-09-07

Similar Documents

Publication Publication Date Title
EA202091709A1 (ru) Ингибиторы днк-пк
EA202091708A1 (ru) Ингибиторы днк-пк
MX2021008507A (es) Moleculas que se unen al receptor leucocitario similar a inmunoglobulina subfamilia b miembro 3 (lilrb3) y usos para las mismas.
EA201890145A1 (ru) Антитела к фактору xi и способы их применения
EA202091747A1 (ru) Составы антитела b7-h4
EA201791867A1 (ru) Бициклические гетероциклы как ингибиторы fgfr4
EA202290054A1 (ru) Полиспецифические антитела, содержащие только тяжелые цепи, которые связываются с cd22 и cd3
EA202192888A1 (ru) Соединения и способы нацеливания на тау человека
EA201290209A1 (ru) Новые модуляторы бензопиран киназы
EA202191380A1 (ru) Антитела к альфа-синуклеину и их применение
EA202090401A1 (ru) Анти-tim-3 антитела и их применение
EA202090372A1 (ru) Универсальные соединения авт и их применение
EA201992083A1 (ru) Модуляторы соматостатина и их применения
EA202092518A1 (ru) Композиции и способы лечения рака
EA202190588A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
EA201991511A1 (ru) Кристаллическая структура гремлин-1 и ингибирующее антитело
EA202192488A1 (ru) Антитела против tsg-6 и их применения
BR112022000855A2 (pt) Moduladores de nlrp3
EA202092125A1 (ru) Антитела против рецептора фолата 1 и их применения
EA202191476A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
EA201991898A1 (ru) Двойные ингибиторы magl и faah
EA202191478A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
EA202190807A1 (ru) Антитела к синуклеину
EA202092305A1 (ru) Соединения в качестве модуляторов сигнализации tlr2
MX2019001579A (es) Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt.